《利福平耐药肺结核诊断流程》解读

Interpretation of Rifampicin-resistant pulmonary tuberculosis diagnostic process

《利福平耐药肺结核诊断流程》是中国防痨协会于2021年5月12日发布的团体标准,于当日起实施。该标准规定了不同技术条件下利福平耐药肺结核患者的诊断流程,即传统药敏检测技术耐药诊断流程、分子生物学耐药检测技术和传统药敏检测技术结合的耐药诊断流程、多色巢式实时荧光定量PCR技术和分子生物学耐药检测技术及传统药敏检测技术结合的耐药诊断流程。笔者对该标准的主要内容和适用条件进行了解读。

The Rifampicin-resistant Pulmonary Tuberculosis Diagnostic Process is a group standard issued by Chinese Antituberculosis Association on May 12,2021 and implemented since then.The standard specifies the diagnostic algorithms of rifampicin resistant pulmonary tuberculosis patients under different technical conditions:the drug resistance diagnosis process of traditional drug sensitivity detection technology,the drug resistance diagnostic progress of combination of molecular biology drug resistance detection technology and traditional drug sensitivity detection technology,multi-color nested real-time fluorescence quantitative PCR,molecular biology drug resistance detection technology and drug resistance diagnosis process of combination of traditional drug sensitivity detection technology.The main contents and applicable conditions of this standard are hereby interpreted.